Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
68.53%
Net Margin
61.46%
Efficiency Metrics
Revenue per Expense Ratio
3.18
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
294.66%
Income Tax Rate
0.03%
EPS
0.2900000000
Balance Sheet Analysis
Current Ratio
5.79
Cash Ratio
4.96
Working Capital
$49.50M
Debt to Equity
4.96
Debt to Assets
82.48%
Equity Ratio
16.63%
Cash Flow Analysis
Operating Cash Flow Ratio
65.24%
Free Cash Flow Ratio
65.24%
CapEx to Revenue
0.00%
Dividends Paid
$17.80M
Stock Buybacks
$309.15M
Total Shareholder Returns
$326.95M
Cash Position Change
8.76%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 0.53%
Detailed Growth Metrics
Core Performance
Revenue
32.43%
Net Income
99.87%
EPS
163.64%
Operating Income
329.97%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
27.69%
Operating Cash Flow
51.87%
Free Cash Flow
51.87%
Balance Sheet Health
Assets
28.28%
Debt
36.19%
Book Value per Share
-8.28%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
0.53%
Shares Outstanding
8.04%
Long Term Trends
3Y Revenue/Share
-20.00%
5Y Revenue/Share
190.55%
3Y Dividend/Share
11.00%
5Y Dividend/Share
-7.30%